Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors.
Affiliation
Ohio State University College of Medicine, Columbus, OH, 43210Issue Date
2016-03-09
Metadata
Show full item recordCitation
Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors 2016 Investigational New DrugsJournal
Investigational New DrugsDOI
10.1007/s10637-016-0336-9Additional Links
http://link.springer.com/10.1007/s10637-016-0336-9Type
ArticleISSN
0167-69971573-0646
ae974a485f413a2113503eed53cd6c53
10.1007/s10637-016-0336-9